Epoetin alfa reduces anemia but raises clot risk in breast cancer
Adding the ESA epoetin alfa to the chemotherapy regimen for high-risk breast cancer improved hemoglobin levels for patients, but it also resulted in increased thrombosis.
Adding the ESA epoetin alfa to the chemotherapy regimen for high-risk breast cancer improved hemoglobin levels for patients, but it also resulted in increased thrombosis.
Although the risks of erythropoietin-stimulating agents can outweigh the benefits, select patients may benefit.